Global & Mexico Cancer Therapeutics Market to 2031

The cancer therapeutics market in Mexico is witnessing robust growth, driven by demographic shifts, economic development, and enhancements in healthcare infrastructure. According to the International Agency for Research on Cancer (IARC), approximately 210,000 new cancer cases were recorded in Mexico in 2022. Among these, breast cancer was the most prevalent, accounting for 15% of all diagnoses, followed by prostate cancer. The rising incidence of cancer is fueling demand for advanced treatment options, which in turn is propelling market expansion through innovation in drug development, personalized therapies, and increased investments in research and medical infrastructure.

The Mexican government has undertaken significant initiatives to improve healthcare accessibility, including the expansion of cancer care centers and the integration of advanced diagnostic tools. A key development was the establishment of the National Cancer Institute (INCan) as a regional center for cancer research and treatment, strengthening both clinical and scientific capacities. In July 2024, Zydus Lifesciences Ltd obtained marketing authorization from Mexico’s regulatory body for its Trastuzumab biosimilar, Mamitra, which is used to treat various forms of cancer. This approval marked an important step in the company’s strategy to broaden its presence in new markets and improve patient access to cost-effective, life-saving oncology therapies.